Phaseline

Companies › PolyActiva

PolyActiva: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PA5108 Ocular Implant
unclear - combination product for ocular delivery
–Phase 2Glaucoma, Open-AngleNov 2026
PA5346 Ocular Implant
Biodegradable ocular implant for intraocular pressure reduction
–Phase 1Open Angle Glaucoma (OAG)Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06964191PA5108 Ocular ImplantPhase 2Glaucoma, Open-AngleOphthalmologyNov 2026
NCT06964061PA5346 Ocular ImplantPhase 1Open Angle Glaucoma (OAG)OphthalmologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.